Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Do a5GABAA Receptors Mediate the Antidepressant Properties of Nitrous Oxide?
EF 2023-24
Résumé
About 12% of the population will suffer from depression in their lifetime, with significant negative impact on individuals, families, and society. However, current therapies can take weeks to work and are ineffective for many patients, which has led scientists to explore potential new treatments for depression.
Nitrous oxide (N2O) is a general anesthetic gas discovered 250 years ago. It is widely used for surgery, dental procedures, and giving birth, so its safety is well established. In the last decade, trials have found that brief N2O exposures have immediate and long-lasting benefits with few side effects for patients with depression. However, it is not yet known how N2O treats depression.
Our group specializes in research on a brain receptor called the ?-aminobutyric acid type A receptor (GABAAR). Recent work has found that increased function of a subpopulation of GABAAR contributes to depression, and we believe this may underpin N2O’s antidepressant effects. We hypothesize that N2O helps depression by reducing GABAAR activity, which may persist long after treatment.
We will test our hypothesis with mice conditioned to model human depression. The mice will breathe either a mixture of N2O or regular air before depression-like behavior is investigated. We will also measure the activity of certain proteins inside N2O-treated cells from the mouse brain, as well as electrical signals recorded from the cells, to identify key steps in N2O’s antidepressant activity.
This work has the potential to expand N2O’s use for patients with depression by illuminating a novel mechanism of action. We may also identify uses of N2O to benefit patients with other disorders associated with increased GABAAR activity, such as cognitive disorders, stroke, and Alzheimer’s disease.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
505901
Name
Brenna Connor
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Do a5GABAA Receptors Mediate the Antidepressant Properties of Nitrous Oxide?
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Behaviour; Cellular Neurobiology; Depression; Electrophysiology; Gabaa Receptors; Mice; Molecular Neurobiology; Nitrous Oxide; Tonic Inhibition
Abstract
About 12% of the population will suffer from depression in their lifetime, with significant negative impact on individuals, families, and society. However, current therapies can take weeks to work and are ineffective for many patients, which has led scientists to explore potential new treatments for depression.
Nitrous oxide (N2O) is a general anesthetic gas discovered 250 years ago. It is widely used for surgery, dental procedures, and giving birth, so its safety is well established. In the last decade, trials have found that brief N2O exposures have immediate and long-lasting benefits with few side effects for patients with depression. However, it is not yet known how N2O treats depression.
Our group specializes in research on a brain receptor called the ?-aminobutyric acid type A receptor (GABAAR). Recent work has found that increased function of a subpopulation of GABAAR contributes to depression, and we believe this may underpin N2O’s antidepressant effects. We hypothesize that N2O helps depression by reducing GABAAR activity, which may persist long after treatment.
We will test our hypothesis with mice conditioned to model human depression. The mice will breathe either a mixture of N2O or regular air before depression-like behavior is investigated. We will also measure the activity of certain proteins inside N2O-treated cells from the mouse brain, as well as electrical signals recorded from the cells, to identify key steps in N2O’s antidepressant activity.
This work has the potential to expand N2O’s use for patients with depression by illuminating a novel mechanism of action. We may also identify uses of N2O to benefit patients with other disorders associated with increased GABAAR activity, such as cognitive disorders, stroke, and Alzheimer’s disease.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Brenna, Connor
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~